Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: April 2, 2026, 3:55 am
Author: Getaka|Social: XLinkedIn
Stock Ticker - BSE: 532660 | NSE: VIVIMEDLAB

Vivimed Labs Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹10.63Undervalued by 92.22%vs CMP ₹5.53

P/E (15.0) × ROE (15.0%) × BV (₹5.79) × DY (2.00%)

Defaults: P/E=15, ROE=15%

₹12.20Undervalued by 120.61%vs CMP ₹5.53
MoS: +54.7% (Strong)Confidence: 58/100 (Moderate)Models: All 2: Undervalued
ModelCategoryValueWeightSignal
PE-ROEEarnings₹15.3263%Under (+177%)
Revenue MultipleRevenue₹7.0038%Under (+26.6%)
Consensus (2 models)₹12.20100%Undervalued
Key Drivers: EPS CAGR 44.1% lifts DCF — verify sustainability.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: 44.1% · Defaults: P/E=15, ROE=15%

*Investments are subject to market risks

Investment Snapshot

45
Vivimed Labs Ltd scores 45/100 (Average)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health34/100 · Weak
ROCE 8.1% AverageROE 0.0% WeakD/E 0.64 ModerateInterest Coverage 0.0x RiskyProfitable 0/5 years Inconsistent
Smart Money50/100 · Moderate
FII holding stable No changePromoter holding at 7.8% Stable
Earnings Quality75/100 · Strong
OPM expanding (-52% → -17%) ImprovingWorking capital: -255 days (improving) Efficient
Quarterly Momentum35/100 · Weak
Revenue (4Q): -22% YoY Declining
Industry Rank30/100 · Weak
ROCE 8.1% vs industry 16.4% Below peers3Y sales CAGR: -21% Shrinking

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Share Price and Basic Stock Data

Last Updated: April 2, 2026, 3:55 am

Market Cap 45.8 Cr.
Current Price 5.53
Intrinsic Value₹12.20
High / Low 29.4/5.15
Stock P/E
Book Value 5.79
Dividend Yield0.00 %
ROCE8.10 %
ROE%
Face Value 2.00
PEG Ratio0.00

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Vivimed Labs Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Lactose (India) Ltd 106 Cr. 84.2 137/76.021.9 49.60.00 %12.9 %9.69 % 10.0
MPS Pharmaa Ltd 3.15 Cr. 1.65 3.17/1.57 0.330.00 %9.79 %59.0 % 10.0
Gujarat Themis Biosyn Ltd 2,692 Cr. 247 479/22256.3 24.30.27 %27.3 %21.7 % 1.00
Gujarat Terce Laboratories Ltd 25.3 Cr. 32.5 68.4/29.0 10.10.00 %41.4 %14.6 % 10.0
Gujarat Inject (Kerala) Ltd 120 Cr. 82.1 82.1/17.0481 6.930.00 %13.5 %11.0 % 10.0
Industry Average19,815.15 Cr1,053.8453.84201.200.39%16.35%15.16%6.10

All Competitor Stocks of Vivimed Labs Ltd

Quarterly Result

MetricSep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
Sales 44.2255.7437.0335.3533.6441.4638.6229.3724.7736.5125.6121.3920.61
Expenses 53.5360.87201.3235.6839.5440.1967.0940.3725.4135.4628.0821.6721.56
Operating Profit -9.31-5.13-164.29-0.33-5.901.27-28.47-11.00-0.641.05-2.47-0.28-0.95
OPM % -21.05%-9.20%-443.67%-0.93%-17.54%3.06%-73.72%-37.45%-2.58%2.88%-9.64%-1.31%-4.61%
Other Income 0.150.050.680.112.200.047.630.060.030.074.220.380.21
Interest 8.859.228.5210.6611.8913.21-33.330.300.430.481.740.581.66
Depreciation 4.024.0295.924.704.704.705.844.014.106.625.505.014.90
Profit before tax -22.03-18.32-268.05-15.58-20.29-16.606.65-15.25-5.14-5.98-5.49-5.49-7.30
Tax % 0.00%0.00%-0.77%0.00%0.00%-3.31%20.90%0.00%0.00%0.00%2.19%0.00%0.00%
Net Profit -22.03-18.31-265.99-15.58-20.30-16.055.26-15.25-5.14-5.98-5.60-5.49-7.30
EPS in Rs -2.66-2.21-32.08-1.88-2.45-1.940.63-1.84-0.62-0.72-0.68-0.66-0.88

Last Updated: March 3, 2026, 1:50 pm

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 26, 2026, 10:16 am

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 1,3511,3801,3461,4621,1861,3151,059861237187149116104
Expenses 1,1391,1561,1111,0579711,1351,049830245374182129107
Operating Profit 2122242344042151801032-8-187-33-13-3
OPM % 16%16%17%28%18%14%1%4%-3%-100%-22%-11%-3%
Other Income 861181023810111045
Interest 67868468827061564036334
Depreciation 666661585667675618108202022
Profit before tax 87781002868666-109-70-65-331-46-32-24
Tax % 24%7%16%25%11%13%-0%3%4%-1%-1%0%
Net Profit 6672842147657-109-72-68-329-45-32-24
EPS in Rs 8.208.9010.3326.419.446.95-13.16-8.67-8.16-39.62-5.48-3.85-2.94
Dividend Payout % 7%-0%-0%2%4%-0%-0%-0%-0%-0%-0%-0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)9.09%16.67%154.76%-64.49%-25.00%-291.23%33.94%5.56%-383.82%86.32%28.89%
Change in YoY Net Profit Growth (%)0.00%7.58%138.10%-219.25%39.49%-266.23%325.17%-28.39%-389.38%470.15%-57.43%

Vivimed Labs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:-22%
5 Years:-36%
3 Years:-21%
TTM:-24%
Compounded Profit Growth
10 Years:%
5 Years:11%
3 Years:15%
TTM:52%
Stock Price CAGR
10 Years:-21%
5 Years:-25%
3 Years:-20%
1 Year:%
Return on Equity
10 Years:%
5 Years:%
3 Years:%
Last Year:%

Last Updated: September 5, 2025, 1:51 pm

Balance Sheet

Last Updated: December 4, 2025, 2:12 am

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 16161616171717171717171717
Reserves 48047950571888560249341534823-22-52-65
Borrowings 9581,0761,0151,0111,1491,2801,268326359379377376384
Other Liabilities 404327519317343431432532543658579580588
Total Liabilities 1,8581,8982,0552,0622,3942,3292,2101,2891,2661,076950921924
Fixed Assets 8088138148791,0359651,045502520436418408393
CWIP 389094766512289604021211721
Investments 03333386199199199168168168
Other Assets 1,0119921,1441,1041,2901,239990529507421343328342
Total Assets 1,8581,8982,0552,0622,3942,3292,2101,2891,2661,076950921924

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + -1181401545821422805672835-24-2
Cash from Investing Activity + -291-107-190-68-164-89-196404-16-528-5
Cash from Financing Activity + 419-424135186-33872-1,015-10-34-65
Net Cash Flow 11-842544-5-44-441-3-2-1
Free Cash Flow -2771695-11-142333-331,0841130-26-6
CFO/OP -55%63%66%23%30%243%972%1,720%-352%-19%73%13%

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow-746.00223.00233.00403.00214.00179.009.00-294.00-367.00-566.00-410.00-389.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 9487885085998646134145203233
Inventory Days 249244294329411397396263573216327358
Days Payable 106107981221542071793510074225240
Cash Conversion Cycle 237224285258342288303274607286305351
Working Capital Days 574358551216821677195-15-171-255
ROCE %12%11%12%22%9%7%-3%-1%-3%-52%-9%-8%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 20.94%20.94%20.94%20.94%20.94%20.94%20.94%20.94%20.94%7.76%7.76%7.76%
FIIs 1.64%1.64%1.64%1.64%1.64%1.64%1.64%1.64%1.64%1.64%1.64%1.64%
Government 0.12%0.12%0.12%0.12%0.12%0.12%0.12%0.12%0.12%0.12%0.12%0.12%
Public 77.30%77.30%77.29%77.30%77.29%77.30%77.30%77.30%77.30%90.47%90.47%90.47%
No. of Shareholders 50,68349,50349,03849,02749,01649,01249,00349,00548,95748,92848,92549,221

Shareholding Pattern Chart

No. of Shareholders

Vivimed Labs Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

This stock is not held by any mutual fund.

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 2.002.002.002.002.00
Basic EPS (Rs.) -3.85-5.48-39.62-8.16-8.67
Diluted EPS (Rs.) -3.74-5.32-39.62-7.92-8.42
Cash EPS (Rs.) -1.42-3.08-26.55-5.95-1.98
Book Value[Excl.RevalReserv]/Share (Rs.) -8.82-5.240.1739.3547.47
Book Value[Incl.RevalReserv]/Share (Rs.) -4.24-0.654.7543.9352.05
Revenue From Operations / Share (Rs.) 14.0217.9822.5728.62103.90
PBDIT / Share (Rs.) -1.05-2.13-22.47-0.814.77
PBIT / Share (Rs.) -3.49-4.53-35.55-3.02-1.93
PBT / Share (Rs.) -3.84-4.82-39.88-7.82-8.43
Net Profit / Share (Rs.) -3.85-5.48-39.62-8.16-8.67
NP After MI And SOA / Share (Rs.) -3.85-5.48-39.62-8.16-8.67
PBDIT Margin (%) -7.46-11.82-99.59-2.864.58
PBIT Margin (%) -24.85-25.19-157.53-10.56-1.85
PBT Margin (%) -27.39-26.82-176.72-27.32-8.10
Net Profit Margin (%) -27.48-30.48-175.59-28.50-8.34
NP After MI And SOA Margin (%) -27.48-30.48-175.59-28.50-8.34
Return on Networth / Equity (%) 0.000.00-23087.35-20.73-18.26
Return on Capital Employeed (%) -5.63-6.94-52.25-2.80-1.68
Return On Assets (%) -3.47-4.77-33.24-5.34-5.57
Long Term Debt / Equity (X) -0.86-1.4643.790.180.14
Total Debt / Equity (X) -5.14-8.67266.031.100.64
Asset Turnover Ratio (%) 0.120.150.160.180.12
Current Ratio (X) 0.800.830.781.361.55
Quick Ratio (X) 0.650.670.590.710.80
Inventory Turnover Ratio (X) 1.891.251.170.570.24
Interest Coverage Ratio (X) -2.94-7.25-5.19-0.170.73
Interest Coverage Ratio (Post Tax) (X) -9.85-15.29-8.15-0.70-0.33
Enterprise Value (Cr.) 0.000.00430.11471.51378.03
EV / Net Operating Revenue (X) 0.000.002.301.990.43
EV / EBITDA (X) 0.000.00-2.31-69.449.57
MarketCap / Net Operating Revenue (X) 0.000.000.290.500.15
Price / BV (X) 0.000.0038.870.360.33
Price / Net Operating Revenue (X) 0.000.000.290.500.15
EarningsYield 0.000.00-5.94-0.56-0.54

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Vivimed Labs Ltd. is a Public Limited Listed company incorporated on 22/09/1988 and has its registered office in the State of Karnataka, India. Company's Corporate Identification Number(CIN) is L02411KA1988PLC009465 and registration number is 009465. Currently Company is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company's Total Operating Revenue is Rs. 103.60 Cr. and Equity Capital is Rs. 16.58 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
PharmaceuticalsPlot No. 78/A, Kolhar Industrial Area, Bidar Karnataka 585403Contact not found
Management
NamePosition Held
Dr. Manohar Rao VaralwarChairman & Wholetime Director
Mr. Santosh VaralwarManaging Director
Mr. Sandeep VaralwarWhole Time Director
Ms. Aparna BidarkarIndependent Director
Ms. Subbarathnamma PalepuIndependent Director
Mr. Jarugula Siva PrasadIndependent Director

FAQ

What is the intrinsic value of Vivimed Labs Ltd and is it undervalued?

As of 20 April 2026, Vivimed Labs Ltd's intrinsic value is ₹12.20, which is 120.61% higher than the current market price of ₹5.53, suggesting the stock is undervalued. This is calculated using the PE ratio method factoring in ROE (%), book value (₹5.79), dividend yield (0.00 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Vivimed Labs Ltd?

Vivimed Labs Ltd is trading at ₹5.53 as of 20 April 2026, with a FY2026-2027 high of ₹29.4 and low of ₹5.15. The stock is currently near its 52-week low. Market cap stands at ₹45.8 Cr..

How does Vivimed Labs Ltd's P/E ratio compare to its industry?

Vivimed Labs Ltd has a P/E ratio of , which is below the industry average of 53.84. This is broadly in line with or below the industry average.

Is Vivimed Labs Ltd financially healthy?

Key indicators for Vivimed Labs Ltd: ROCE of 8.10 % is on the lower side compared to the industry average of 16.35%; ROE of % is below ideal levels (industry average: 15.16%). Dividend yield is 0.00 %.

Is Vivimed Labs Ltd profitable and how is the profit trend?

Vivimed Labs Ltd reported a net profit of ₹-32 Cr in Mar 2025 on revenue of ₹116 Cr. Compared to ₹-68 Cr in Mar 2022, the net profit shows a mixed trend.

Does Vivimed Labs Ltd pay dividends?

Vivimed Labs Ltd has a dividend yield of 0.00 % at the current price of ₹5.53. The company is currently not paying meaningful dividends.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Vivimed Labs Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports